Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531552 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TDP1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL3192305 | 0.83 | NPSR1 (0.46) | ALDH1A1CYP1A2GAAMAPTMEN1 | |
| SCHEMBL3175739 | 0.81 | RAB9A (0.39) | ALDH1A1CYP1A2GAAMAPTATM | |
| SCHEMBL10686284 | 0.80 | NOTUM (0.45) | ALDH1A1CYP1A2GAASMN1; SMN2HPGD | |
| SCHEMBL10685631 | 0.78 | MAPT (0.58) | ALDH1A1GAAMAPTTDP1MEN1 | |
| SCHEMBL3186815 | 0.76 | ADORA1 (0.47) | ALDH1A1GAAMAPTL3MBTL1MEN1 | |
| SCHEMBL3188766 | 0.76 | CYP1A2 (0.45) | ALDH1A1CYP1A2GAAMAPTSMN1; SMN2 | |
| SCHEMBL4783318 | 0.71 | ALDH1A1 (0.46) | ALDH1A1MAPTATMTDP1L3MBTL1 | |
| SCHEMBL4471265 | 0.70 | RAB9A (0.51) | ALDH1A1CYP1A2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2355240 | 0.70 | NR4A2 (0.63) | ALDH1A1CYP1A2GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-5380730-A | Angiotensin antagonist | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-10 | — | — | US | disclosed |
| WO-1994003453-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| US-5236936-A | Treating hypertension, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0499416-A2 | Pyridine compounds as angiotensin II antagonists, processes for their preparation and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | ALDH1A1 892/4885CYP1A2 1301/4885GAA 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.